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ess under CC BY-NC-Abstract The enormous progress biotechnology, bioinformatics and nanotechnology made in recent years
provides opportunities and scientiﬁc framework for development of biomedicine and constitutes a paradigm
shift in pharmaceutical R&D and drug innovation. By analyzing the data and related information at R&D
level over the past decades, developmental tendency and R&D patterns were summarized. We found that a
growing number of biologics in the pipeline of pharma companies with successful products already in the
market though, small molecular entities have primarily dominated drug innovation. Additionally, small/
medium size companies will continue to play a key role in the development of small molecule drugs and
biologics in a multi-channel integrated process. More importantly, modern and effective R&D strategies in
biomedicine development to predict and evaluate efﬁcacy and/or safety of 21st century therapeutics are
urgently needed. To face new challenges, developmental strategies were proposed, in terms of molecular
targeted medicine, generic drugs, new drug delivery system and protein-based drugs. Under the current
circumstances, interdisciplinary cooperation mode and policy related to drug innovation in China were deeply
discussed as well.
& 2014 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical
Sciences. Production and hosting by Elsevier B.V. Open access under CC BY-NC-ND license.l Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by
2
63.com (Changxiao Liu), ppconstantinides@bpddc.com (Panayiotis P. Constantinides).
itute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association.
ND license.
Figure 1 “One in ten-thousand” model for drug innovation of
research and development.
Figure 2 Comparison of new molecular entity and biological application
since 1997 (Source from FDA websites, Evaluation Pharm).
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Bioscience is now rapidly expanding in the 21st century.
Advances in biology/biotechnology, bioinformatics and nanotech-
nology provide opportunities and a scientiﬁc framework for
biomedicine, which can have signiﬁcant impact on conventional
research and development (R&D) and drug innovation, even a
revolutionary change. The objective of this article is to further
discuss the aforementioned areas by reﬂecting on the Session on
R&D in Drug Innovation during the Bioeconomy 2013 conference
in China along with lessons learned and future perspectives, and
their implications for the growth of biomedicine in China1–20. Big
Pharma's challenges which are becoming opportunities for biotech
and startup companies include: (1) R&D spending is growing
faster than sales growth, (2) drug discovery is lagging relative to
industry growth needs, (3) increase presence of large molecules in
big pharma's pipeline, (4) increasing need for in-licensing products
and technologies, and (5) blockbuster drugs are going off patent.
As a result of these changes, the number of joint ventures and
collaborations between academia, government and industry has
exponentially grown in recent years.
Pharmaceutical innovation has led to a decline in industry
productivity. Despite the increased investment in R&D by the
industry, the number of new molecular entities (NME) achieving
marketing authorization is not increasing. Over the past 20 years,
the number of Investigational new drugs (INDs) approved by
regulatory agency did not increase as anticipated with enhanced
quality control level and strict safety assessment as well as many
molecular targets identiﬁed, while those drugs currently applied in
clinical for long time have demonstrated their values, suggesting
that high investment, development of technology and “-omics”,
such as proteomics and genomics have not reduced the R&D risk
effectively and enhance efﬁciency1,2,8.
In light of these scenarios, various strategies have been adapted
in order to increase R&D efﬁciency and productivity8. At the drug
discovery level, increased use of bioinformatics and computer
modeling along with accelerated proof of concept studies and
enhanced input from commercial and marketing have proved to be
useful. The use of biomarkers and translational research in clinical
trials is regarded as a powerful tool and used broadly in the
pharmaceutical industry. Implementation of risk mitigation strate-
gies and exploitation of outsourcing and strategic partnerships can
further improve R&D efﬁciency and productivity.2. Innovation trends in biomedicine
2.1. Conventional R&D pattern with high cost, high risk and
low productivity is not sustainable
The conventional R&D pattern in drug innovation started in 1960s
and it is always accompanied by high cost, high risk and low
efﬁciency. By analyzing the ratio of the number of drugs approved
for marketing by Federal Drug Administration (FDA) to that of
active ingredients/molecules at the drug discovery stage, it remained
at approximately 0.01% (Fig. 1) that is “one in ten-thousand”
molecules make it to the market indicating the need for tremendous
investment in R&D as a result of the extremely high potential of
failure in the course of drug development. High rate of failure in
drug development continued despite demands in high drug product
quality and safety assessment along with technological advances.The recently published data sourced from Bristol-Myer–Squibb
and other 5 giant pharmaceutical companies revealed that of the 6
drug candidates that were terminated at phase III clinical trial in
2012, 4 were eliminated by efﬁcacy and with the other 2 were
safety issues. Efﬁcacy and safety issues were considered as the
main causes of failure at the stage of phase III. A molecule is not a
drug, neither is active one and “druggability” is a key factor in the
systematic process from molecule to drug, while translational
research with “risk evaluation” is the decisive element. Unfortu-
nately, this key problem has not been properly considered and
addressed by multidimensional investigation through science,
technology, policy, regulatory, ethnics and industry, analyzing
bottleneck and other issues in common. However, a deep under-
standing of the issues using traditional models of drug develop-
ment R&D and focusing on key challenges and opportunities is
critical to building and adapting new innovative models of drug
R&D.
2.2. Developing small molecule drug is still the mainstream
approach
The nature of the pharmaceutical industry is such that the main
driver for its growth is innovation21. Biomedicine R&D is
becoming increasingly challenged due to lower productivity and
thus pharmaceutical companies have opened their R&D organiza-
tions to external innovation14,15,20.
Fig. 2 compares new molecular entities and biological applica-
tions from 1997 to 2009. R&D spending was increased more than
3-fold since 1997 while NME approvals dropped by 44%. This
trend is expected to continue given increased regulatory scrutiny;
NME approvals decreased by 4.8% 1997–2009, while R&D spend
increased by 10.7%; 45 NMEs and therapeutic biological applica-
tions (BLAs) were approved in 1997 which fell to 25 in 2009; in
2009, the industry spent a total of $125 billion (BN) R&D vs.
C. Liu et al.114$55BN in 1999, a 128% increase. Small molecule drugs are with
obvious advantage. Based on the R&D level and progress made,
new molecular entities will still be dominated in drug innovation
for the next decade. Perspective of small/medium size enterprises
via multichannel integration will be very promising20.
In 2011, 35 new drugs were approved by the regulatory agency for
marketing, based on long term efforts made. The number of new drugs
approved is higher than the average level of approved drugs which is
20 per year. Of the 35 new drugs approved, 25 (71%) were new
molecular entities, while new antibody therapeutics was only one (3%),
and four kinase inhibitors for anticancer treatment (11%). Similar
situation was observed in 2012 with 39 new drugs approved achieving
new record for the last decade. The number of new drugs approved
was 27 NMEs, 1 antibody and 7 kinase inhibitors, respectively, in
terms of category. Since the ﬁrst antibody therapeutic was developed in
1994, only 42 were approved for marketing up to date, averaging 2–3
new antibodies launched each year. Due to the quality, efﬁcacy and
safety issues, in particular the immunogenicity, as well as R&D
challenges and heavy demands for biologics, the number of new
biologic therapeutics remains low. In addition, treatment costs for
government and the patients, as well as reimbursement burden for
healthcare providers and medical insurance companies, have contrib-
uted to the low market share of biologic therapeutics. In developed
countries, for instance in United States, the portion of generic drugs
was over 80% in prescription, which limited the use of innovators'
biotech medicine.2.3. Small/medium size enterprises, key players in drug
innovation
This analysis shows that the rate of production of new drugs by these
companies has been constant since they began producing drugs with
some variability in rates between companies. It is a fact that the cost
per new molecular entity has been steadily increasing over the last
decades. A puzzling trend in recent years, however, has been the
gradual erosion in the share of innovation that is captured by NMEs
discovered by large pharmaceutical companies. Since the early
1980s, their share of NMEs has declined from 75%, a level that
had been constant since 1950, to 35% (Fig. 3a). At the same time, the
share of NMEs that is attributable to small biotechnology and
pharmaceutical companies has almost tripled, from 23% to nearly
70%. Since 2004, small companies have consistently matched or
outperformed their larger competitors. The expected share of NMEs
generally follows these trends until 2004, when they stabilized at
about 50% each22.
The increase in the NME output from small companies has been
driven primarily by two factors. The ﬁrst one is a rise in the number of
small companies producing NMEs, which nearly doubled from 78 to
145 during the 1980s and 1990s. This was facilitated by the growth of
venture capital that has funded much of the “biotech boom”. Second,
the mean annual NME output of small companies has increased from
0.04 to 0.12 since 1995, owing to the emergence of new, more efﬁcient
companies (Fig. 3b). Conversely, the decline in the output of large
companies has been driven by the dwindling number of large
pharmaceutical companies, which has decreased by 50% over the past
20 years22.
By comparison of achievement in innovation, seven new drugs
were developed by giant pharmaceutical companies in 2011, two
products were co-developed. However, the number of new drugs
through company merging and collaboration with small/medium
size companies were up to 13. Similarly, the number of new drugsfrom sources mentioned above were 10, 1 and 8, respectively, in
2012. Apparently, small molecule drugs were still favored; also
small/medium size companies played a key role in drug inno-
vation.
Although the number of new drugs declined over the past years,
the new drugs that giant pharmaceutical companies acquired from
small/medium competitors were increasing (Fig. 4). In terms of the
amount of new drugs at pre-clinical, phase I, II, III clinical trial
stages, small/medium size companies have become major players
in drug innovation, particularly with more drugs at phase II, III and
on the market and which are originated from small/medium size
companies. Their outputs ﬁlled the pipeline of giant companies
with best-selling drugs14.
In light of the open innovation spirit, American pharmaceutical
companies are integrating into their drug development process
the R&D of small/medium size companies, universities/research
institutes, contract development and manufacturing organizations
(CDMO) and other partners. As presented in Bioeconomy 2013,
shortly after Pharmasset was merged with Gilead, an 11 billion
United State dollars (USD) deal, the market value of Gilead boosted
sharply from 37 to 83 billion USD15, as Sofosbuvir, the orally
administrated/non-combined interferon, has been approved by FDA
for marketing in 2013 for treatment of HCV. In addition, Zytiga
(abiraterone acetate), the CYP17 inhibitor that is able to form non-
reversible products to lower its activity by reducing the biosynthesis
of androgenic hormone, was initially discovered by British Cancer
Institute. The product was then transferred to Cougar Biotech for
clinical trials, and eventually purchased by Johnson & Johnson at
phase II in 2009 at 1 billion USD. After approval, the sale for ﬁrst
year was over 1 billion. There were also other successful cases in
Japan, UK, Canada and Australia.
Sixty six of the 98 companies studied launched only one drug
this decade. The costs absorbed by these companies can be taken
as a rough estimate of what it takes to develop a single drug. The
median cost per drug for these singletons was $350 million
(Table 1), but for companies with more drugs approved, the cost
per drug went up – until it hit $5.5 billion for companies that have
brought to market between eight to 13 drugs over a decade23.2.4. Development of new biological products and risk
assessment
Emerging tumor-targeted medicines opened a new age of clinical
application of pharmacogenomics. After the ﬁrst targeted drug
Mabthera was discovered, more products, for example, Glivec,
Iressa, Tarceva, Erbitux, Avastin, Crizotinib, Zelboraf, Conmana
were developed. Particularly, the product Conmana has strong
impact on domestic pharmaceutical industry. Of 4 monoclonal
antibody products co-developed by Huahai and OncoBiologics,
three are targeted therapeutics. In 2013, Beida–Amgen launched a
new project of marketing Vectibix.
Apart from anti-cancer medicines, FDA lists over 100 drugs and 40
biomarkers. In terms of importance of clinical tests, biomarkers were
categorized into three levels: (1) mandatory, (2) high risk patient, and
(3) recommended. Drugs and biomarkers related, for example,
Clopidogrel (CYP2C19), warfarin (CYP2C9þVKOCR) for anti-
coagulation, β receptor blockers (CYP2D6), statins: ApoE2, LDL
receptor, SLOCR, the anti-infectious/HCV agents, interferon, IL28B
gene, HLA gene of HIV and NAT gene of TB, Carbamazepine for
psychiatric treatment, HLA-B1502 gene, and Ivacaftor (CFTR gene)
are now required to be diagnosed through gene testing for the rational
Figure 3 The mean annual new molecular entitie (NME) output of large and small companies. a, actual versus expected shares of NMEs for large
and small pharmaceutical companies; b, mean annual NME output for small companies.
Figure 4 The contribution of small/medium size companies to
pharmaceutical industry. (Sourced from Burrill & Co. (San Francisco).
2010 year to date (YTD) is through September 30.
Table 1 Relationship between number of drugs approved
and R&D cost per drug*.






nSources: InnoThink Center for Research in Biomedical Innova-
tion; FactSet Systems.
Research and development in drug innovation 115use of the corresponding drugs. Peripheral blood sample, tissues, DNA,
SNP, recombinant gene, mRNA, as well as gene expression level are
tested for in vitro diagnosis. Development of therapeutic and diagnostic
agents is very helpful for enhancing efﬁcacy and safety and, all types
of synergies and collaborative efforts should be taken into considera-
tion. Furthermore, emerging challenges, for example, patents on new
molecular entities and biomarkers, clinical testing issues, registration of
patients in clinical trials, recognition of medical practitioners, redeﬁning
the role of pharmacists, cooperation between pharmaceutical and
diagnostic companies, and medical insurance/healthcare providers'
issues, are all associated with science, technology, cooperation, policy
and shared proﬁts.3. Reﬂecting on R&D in drug innovation
3.1. Higher productivity
The constraints resulting from short-term business decisions, and the
harvesting of all “low-hanging fruit”, have been cited as the major
causes for the decreased productivity and a change in the preclinical
research culture is equally culpable. Current trends in biomedical
research have led to a decreased emphasis on the null hypothesis/data-
driven approach. A trend toward qualitative rather than quantitative
science; an implicit assumption that all targets represent a viable
starting point for drug discovery efforts24. Biomedical research effortsdirected toward drug discovery, both in academia and industry should
prioritize genuine innovation over technology and thus allow efforts in
preclinical research to play a key role in the solution to the shortfall in
new drug applications24. Pharmaceutical R&D is a very complex
organization and requires integration of multiple disciplines, and special
skill sets and talent to execute company's business strategy and timely
achieve objectives. The head of R&D with broad technical skills and
management experience is critical to the success of the organization8.
Currently, high cost and risk, as well as low efﬁciency are main
bottlenecks in drug innovation. The strategies on how to enhance
efﬁciency in R&D vary between different companies. The R&D
process should be customized based on the position and formulated
targets. For instance, the resource and experience can be accumulated
through development of generic products. Although, “ﬁrst-in-class”
strategy in drug innovation will be the key approach to lead pharma
innovation, “me better” is still the main long-term strategy for most of
the domestic pharmaceutical companies. However, the “fast follow-on”
pattern will become active in the next decade. Based on generic drugs,
a giant pharmaceutical company driven by innovation and internatio-
nalization will emerge and expand in China soon.
3.2. Integration and rational allocation of resources
Technology innovation is not only the fundamental principle and
engine of developing pharmaceuticals and the economy, but also the
decisive factor in competition. We should pay more attention to the
C. Liu et al.116new thinking in developing new medicines3. For example, discovery
of new drug targets in combination with application of genomics is
now able to quickly identify and conﬁrm the targets; development of
new drugs with recognition of metabolic pathways and genetic diffe-
rences can be more accurate and efﬁcient; matching drug discovery
technologies of drugs and genomics enhance the safety in clinical use;
discovery of biomarker improves the accuracy of prediction; applica-
tion of network pharmacology technology and virtual studies offer
new approaches for high-throughput screening of new drugs. In
particular, the gene mutant model on a large scale and relevant rules,
recognition and studies mentioned in the forum can be beneﬁcial to
speed up the innovation process16,17. With the knowledge of new
strategies in drug development, integration of various processes can
signiﬁcantly enhance R&D capacity and avoid waste.
Exploration of R&D patterns in drug innovation is the key issue
and common to all companies. The pharma industry can rapidly
develop through intrinsic growth and/or, peripheral expansion.
Domestic and overseas companies should focus on the opportu-
nities for innovative drug products. Cooperation with international
healthcare industry investment foundations may be useful for
obtaining global resources and funding.
Translational medicine plays a key role and also represents an
integration strategy in drug development. In pre-clinical studies of
targets and drug candidates, the large scale gene mutant animal model
can be directly applied in drug screening to rapidly identify the drug
targets. Beyond the good animal model practice, the principle of
selection and conﬁrmation may also help to improve the efﬁciency of
translational research at early stage17. Application of translational
research with “biology ﬁrst” pattern into the drug development
practice was illustrated in a case study, where productivity and
outputs were improved by applying biomarker technology combined
with clinical genomics9. Meanwhile, development of targeted therapy
and genomics for personalized medicine has important impact in
translating drug candidates into clinical treatment, safety and efﬁcacy.
Novel approaches for clinical development and trial design could
have a key role in overcoming some of these challenges by improving
efﬁciency and reducing attrition rates25. During the exploratory phase
of development, this new model uses all available knowledge and tools
(Fig. 5), including biomarkers, modeling and simulation, as well as
advanced statistical methodology. Trials are designed to determine
proof-of-concept (POC) and to rigorously establish dose selection that
will enhance the likelihood of success in the conﬁrmatory phase. The
modern designs, tools and knowledge are applied to larger scale studies
with the goals of identifying the target patient population in which the
drug is efﬁcacious, establishing the beneﬁt/risk ratio and conﬁrming the
optimal dose and dosing regimen. The innovative clinical trial designs
such as adaptive or seamless studies compress timelines, improve dose
and regimen selection, and reduce the number of patients assigned to
non-viable dosing regimens.
The scientiﬁc community believes that targeted therapy and
genomics will offer great opportunities in personalized medicine
for patients and the development of companion diagnostics with
respect to the investigational drugs and those on market18.
Although, the implemented national project of drug innovation
provided sufﬁcient support for the research and development process
by optimizing allocation of resources, encouraging innovation and
setting policy guidelines, drug innovation remains challenging20.
Question has been raised on how to perform integration of resources
and rationalize the development pattern and strategy, that is suitable for
the speciﬁc company. To establish advanced innovation systems for
the pharmaceutical industry, there are still many challenges: (1) the
capacity of R&D in drug innovation, the specialists and particularlythe leading scientists, remain limited; and (2) with respect to indus-
trialization and internationalization, regulatory systems established for
the pharmaceutical/biomedical industry and relevant laws and regula-
tions were incomplete.3.3. Developmental strategy of molecular targeted medicines
Drug discovery must be driven not only by medical need and
commercial potential, but also by the areas in which new science is
creating therapeutic opportunities, such as target identiﬁcation and
the understanding of disease mechanisms26. Development of anti-
cancer drugs has evolved from conventional drugs with cytotoxi-
city to molecular targeted medicine. Since Gleevec, the ﬁrst small
molecule targeted medicine, was approved for marketing in 1997,
there are over 30 molecular targeted drugs on the market with
respect to various types of signaling pathways. Molecular targeted
anti-cancer drugs became a reality as multiple signaling molecules
and pathways have been conﬁrmed as useful targets for therapy. In
the 21st century, the developmental strategy of anti-cancer drugs
focuses on molecular targeted drugs with strong cytotoxicity. As
previously mentioned, the discovery of drug targets provides
opportunities for drug innovation, rational use of drugs, persona-
lized medicine and reduction in the side effects.
Discovery and validation of new targets is the focus of global
competition in research and development. The sustained break-
through in screening assays and evaluation technologies is based
on updated theories and technologies of genomics, proteomics,
bioinformatics, system biology, modern detection technologies etc.
The trend in the anti-cancer drug R&D is the design of multi-targets
as well as the discovery of new targets. However, these opportunities
are always accompanied with issues and challenges: (1) the features
of the target, signaling pathways and interaction between the two
might not be accurate, leading to uncertain efﬁcacy; (2) broad
spectrum of targeting and side effects are controversial, particularly
the complicated toxicity caused by inmunogenicity of antibody drugs,
for example the immuno-mediated hepatitis; and (3) to overcome
acquired drug resistance, combination use of drugs has become the
leading edge in the study of molecular targeted drugs20. Regardless of
the development of antibody drugs or antibody–drug conjugates
(ADC), the drug resistance issue has not yet been properly solved.
Thus, study of targeted medicine and relevant molecular biology
fundamentals should be strengthened. Recognition of the features of
multiple targets and regulatory process for most solid tumors, as well
as the current level of translational research cannot explain all clinical
aspects. Based on biomarkers, personalized medicine will be the
primary target of treatment. Development of molecular targeted
medicine and companion diagnostics will have signiﬁcant impact
on clinical trials and treatment. The challenge, however, is how to
identify the biomarker and accurately select signaling molecules for
the rational use of a particular drug.
In recent years, nanotechnology has been increasingly applied
in drug development throughout the drug development value
chain27–29. The development and approval of nanoparticle-based
therapeutics, has strengthen the dialogue between drug developers
and regulatory agencies to accelerate the growth of this important
ﬁeld. Nanoparticle-based therapeutics can confer the ability to
overcome biological barriers, effectively deliver drugs and biolo-
gics, and preferentially target sites of disease28,29. The complexity
of nanoparticles as multi-component three dimensional constructs
requires careful design and engineering, detailed characterization
methods, and reproducible scale-up and manufacturing process to
Figure 5 A new paradigm for clinical development25.
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characteristics, biological behavior, and pharmacological proﬁle27–29.
However, despite the potential advantages of nanoparticles, only a
relatively small number of nanoparticle-based medicines have been
approved and marketed for clinical use, while numerous challenges
and hurdles exist with nanoparticulate drugs that are at different
stages of development. The safety and efﬁcacy of nanomedicines can
be inﬂuenced by minor variations in multiple parameters and need to
be carefully examined and controlled in preclinical and clinical
studies, particularly in reference to their biodistribution, pharmacoki-
netics and potential toxicity27–29.3.4. Developmental strategy of new drug delivery systems
As the investment into R&D sharply declined, many internal R&D
organizations have been downsized or eliminated. Special considera-
tion has been given to novel drug delivery systems (DDS) and it is
estimated that the market size of novel drug delivery system has
reached 153 billion USD in 2011 with an average annual growth rate
of 16% over the past ﬁve years. Development of novel DDS is more
practical than that of a new molecular entity, in terms of efﬁciency,
cost/risk and timeline. For example, Rapamunes, Emends, Tricors
145, Megaces ES, Invegas Sustennas nanocrystalline drug pro-
ducts developed by Elan through nanotechnology have been
approved by FDA28. Several preparations of Shandong Green leaves
pharmaceutical and products developed by other companies have
been approved by either FDA or State Food and Drug Administration
(SFDA) for clinical trials20.
During the past decade, the functions and roles of FDA in
USA have evolved from “legislation, administration of justice” to
“encourage science and innovation to ensure product quality, safety
and efﬁcacy”. Laws/regulations related to drug registration revealed
that for drug safety and efﬁcacy evaluation of raw materials,
pharmaceutical excipients, new technologies and novel formulations
can be beneﬁcial. Most importantly, clinical assessment has become
the key in drug product review. Several nano-drug products as
discussed earlier have been approved for marketing and small/medium
size companies may proﬁt from novel formulations19. Development of
novel DDS particularly those incorporating nanotechnology is limitedby theory, technology, excipients and manufacturing process and
equipment. Cooperation patterns in the nanotechnology ﬁeld will be
further explored and discussed at the global summit on scientiﬁc
regulation 2013.
3.5. Developmental strategy of generic drugs
According to the national strategy and needs, all major pharmaceu-
tical companies have seriously considered the development of generic
drugs as to lower ﬁnancial burden and medical expenses. The
development and use of generic drugs is encouraged by regulatory
agencies and relevant authorities. Top pharmaceutical companies that
are focused on innovative drugs have joined forces with other
companies for the development of generic drug. In addition,
approximately 40% of patents owned by top 20 pharmaceutical
companies are set to expire during 2009–2013.
Development of generic drugs is still dominating in China at this
stage. However, combination of generic and innovative drugs has
become the main approach in developing advanced generic products.
The issue has been raised on how to identify new indications of
currently used medicine, discover new drugs from failed drug
candidates and new pathways of unsuccessful investigational drugs.
Deep understanding and investigation of patents of innovative drugs, in
particular their chemical entity, polymorphism, manufacture, inter-
mediates, formulations and indications may be useful for patent
innovation and protect the interests of products on markets. For
example, generic products can be launched shortly after patent of
innovative chemical entity expired, if patent of polymorphism can be
thoroughly understood. Or new formulation or indications are devel-
oped in advance via technology innovation. Optimization of purity and
safety of innovative products is another approach for domestic industry
to get involved.
3.6. Developmental strategy of protein-based drugs
Up to date, Therapeutic biological applications approved by
regulatory agency for marketing remained limited, since ﬁrst
antibody was launched in 1994. Protein-based drugs sourced
from bio-tech and engineering, however, are undoubtedly a new
C. Liu et al.118class of revolutionary medicine, covering many scientiﬁc ﬁelds
such as genetic engineering, recombinant protein technology,
industrial fermentation, microbiology30. For example, antibody-
based therapies succeeded in treatment of cancer. Thirteen
monoclonal antibodies (mAbs) have been approved for clinical
use in EU and US, as well as hundreds of mAbs, including
bispeciﬁc mAbs and multispeciﬁc fusiong proteins in trials.
Efforts have been made on humanizing the antibody protein
and expanding of the target antigen repertoire. Antibody–drug
conjugates (ADCs) and peptide–drug conjugates (PDCs) have
been developed for delivering potent anti-cancer drugs. Deeper
understanding of action of mechanism is still needed to overcome
main issues limiting applications of biologically sourced medi-
cine, including resistance to therapy, access to targets, complex-
ity of biological systems, individual variation, cancer cell
speciﬁcity, conjugation chemistry, tumor penetration, product
heterogeneity and manufacturing31.
Additionally, absorption, distribution, metabolism and excretion
properties (ADME) of ADCs in trials should be fully characterized
to understand their safety and efﬁcacy. Even the linker existing in
ADCs may have signiﬁcant impact on pharmacokinetic behavior,
observed catabolites in tumor and liver tissues32,33. Also, physico-
chemical, biopharmaceutical and/or pharmacokinetic properties
played a key role in developing novel protein-based drugs. Oral
absorption and aqueous solubility improved, and increasing lipophi-
licity may enhance active transportation, as well as achieve site-
selective delivery. For instance, drug-loaded liposomes are targeted
to tissues/organs by active targeting, based on the attachment of
speciﬁc ligands to the liposomal surface to bind certain antigen on
the targeted cells, while antibody-targeted liposomes have demon-
strated high potential for application34,35.
In addition to the issues addressed above, computational methods
could be used as supplementary, based on crystal structures and/or
homology models, including antibody–antigen docking and energy
calculations, which might provide guidance for experimental studies
to improve afﬁnities and physicochemical properties as to accelerate
the process of obtaining new protein-based drugs36.4. Implications of R&D in drug innovation for the growth of
biomedicine industry in china
4.1. R&D innovation is supported by interdisciplinary
cooperation between government–academia and –industry
Development of innovative drugs (also known as new chemical/
molecular entity) requires heavy investment, and is always
accompanied with long timelines and high potential of failure;
thus, it is not wise for domestic company to follow this approach
as even top pharmaceutical companies cannot afford the cost.
While generic products can fulﬁll the need in China, successful
cases have already demonstrated that products with non-speciﬁc
structure and uncertain mechanism of action can also beneﬁt the
patients. Furthermore, the best-in-class products are determined by
marketing and sales, rather than the R&D process.
According to the current situation of science and technology,
and developmental status of pharmaceutical industry in China,
innovation is required to be supported by interdisciplinary
collaboration by all participants. There are now several issues to
be dealt with, such as: (1) How to make proper judgment on
project quality, (2) appropriate risk evaluation and control, and (3)
set up benchmarks and threshold for innovation.4.2. Innovation is driven by national strategy and policy
In the opening ceremony of Bioeconomy conference 2013, the
secretary of the department of science and technology mentioned that
the portion of research papers in biology and medicine published
during the period of 2003–2013 was over 50% of the growth rate of
global bio/medicine industry and twice as that of GDP. In China, the
impact of innovation in biotechnology and economic development,
the society and people's daily lives has already emerged. Rapidly
developed bioinformatics, life sciences, stem cells and bioprocesses
have promoted the application of biotechnology in agricultural,
medicine, energy and the environment. Special consideration has
been given by central authority to develop biotechnology and relevant
industries. Measures are taken to strength the study of life sciences
and innovation in biotechnology. Plans, policy and regulations have
been proposed: (1) under the guidance of oPlanning of Develop-
ment of Biology Industry4 ando12th 5-Year-Plan on Development
of Biotechnology, biotechnology is supported by resource integration,
(2) establish internationally recognized mechanism of drug review to
promote industrialization of novel medicine, as well as public service
platform for technology incubation and transfer, and quality inspec-
tion in order to reduce the cost for small companies, (3) share of
public/medical resources, for instance, set up effective mechanisms of
public service of state key laboratory and national centers of
engineering technology, as well as regulations of national resources
in biology information, and (4) set up a team of highly skilled
professionals, for instance establish joint training centers between
industry and universities/research institutes, introduce internationally
recognized specialists, identifying and pursuing opportunities for
collaboration, and providing support for ﬁrst-line scientists, particu-
larly of young generation. It is anticipated that the increased presence
of China Pharma/Biotech R&D will meet both local and global
medical and market needs.References
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